Medicus Pharma (NASDAQ:MDCX) said on Wednesday its Phase 2 study of SkinJect (SKNJCT-003), a doxorubicin-containing ...
New Research from Boston Consulting Group Finds Chief Executives May Underestimate Long-Term Risks Closely Linked to CEO Turnover -- AI Ranks Outside Top Five CEO Stressors -- More Than 70% of Top ...
Investors should look out for the shortcomings in remuneration practices highlighted by the study in the companies in which ...
Tourism Kamloops’ CEO says a proposed $89-million convention centre could help the city attract business travellers and bring ...
Apple builds one of the most popular smartphones in the world, giving millions of people access to various ways to doom ...
Dave Banks looked at his engagement survey results: 84 per cent—well above the 78 per cent industry benchmark. His internal ...
The Atlanta Women's Foundation conducted the study ...
How do you focus on lasting success in an era when the pressure to show instant results is relentless? “We choose to go to ...
Oroco Resource Corp. (TSX-V: OCO, OTC: ORRCF) (“Oroco” or the “Company”) announces the resignation of Richard Lock as Chief ...
Older adults in Calgary are facing a growing risk of food insecurity, with rising costs and limited retirement income pushing ...
Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE ...
Dr. Jennifer Buell (President, CEO & Director) reiterated MiNK’s differentiation as “an off the shelf” allogeneic iNKT platform that is “administered without lymphodepletion, without HLA matching,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results